{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:19:29Z","timestamp":1792181969872,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.ejca.2003.11.028","type":"journal-article","created":{"date-parts":[[2004,2,6]],"date-time":"2004-02-06T10:17:37Z","timestamp":1076062657000},"page":"827-836","source":"Crossref","is-referenced-by-count":298,"title":["\u201cOf mice and men\u201d"],"prefix":"10.1016","volume":"40","author":[{"given":"L.R.","family":"Kelland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2003.11.028_BIB1","series-title":"Tumor Models in Cancer Research","first-page":"3","article-title":"Perspective on the history of tumor models","author":"Harrison","year":"2002"},{"key":"10.1016\/j.ejca.2003.11.028_BIB2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1699-0463.1969.tb04520.x","article-title":"Heterotransplantation of a human malignant tumour to the mouse mutant \u201cnude\u201d","volume":"77","author":"Rygaard","year":"1969","journal-title":"Acta Pathology Microbiol. Scand."},{"key":"10.1016\/j.ejca.2003.11.028_BIB3","first-page":"1531","article-title":"Development of invasive tumors in the \u201cnude\u201d mouse after injection of cultured human melanoma cells","volume":"48","author":"Giovanella","year":"1972","journal-title":"JNCI"},{"key":"10.1016\/j.ejca.2003.11.028_BIB4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/301527a0","article-title":"A severe combined immunodeficiency mutation in the mouse","volume":"301","author":"Boxma","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2003.11.028_BIB5","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/jnci\/81.13.988","article-title":"Therapeutic index","volume":"81","author":"Double","year":"1989","journal-title":"Journal National Cancer Institute"},{"key":"10.1016\/j.ejca.2003.11.028_BIB6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0024-3205(95)00254-4","article-title":"In vivo cultivation of tumor cells in hollow fibers","volume":"57","author":"Hollingshead","year":"1995","journal-title":"Life Sciences"},{"key":"10.1016\/j.ejca.2003.11.028_BIB7","doi-asserted-by":"crossref","unstructured":"Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley M.C. Human tumor xenograft models in NCI drug development. In: Teicher B, ed, Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval. Humana Press, Totowa, NJ, 1997, 101\u2013125.","DOI":"10.1007\/978-1-4615-8152-9_6"},{"key":"10.1016\/j.ejca.2003.11.028_BIB8","first-page":"589","article-title":"Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay","volume":"48","author":"Alley","year":"1988","journal-title":"Cancer Research"},{"key":"10.1016\/j.ejca.2003.11.028_BIB9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1983.1","article-title":"The response to chemotherapy of a variety of human tumour xenografts","volume":"47","author":"Steel","year":"1983","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.ejca.2003.11.028_BIB10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/bjc.1978.35","article-title":"An in vitro colony assay for human tumours grown in immune suppressed mice and treated in vivo with cytotoxic agents","volume":"37","author":"Courtenay","year":"1978","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.ejca.2003.11.028_BIB11","series-title":"Tumor Models in Cancer Research","first-page":"113","article-title":"Human tumor xenografts and explants","author":"Fiebig","year":"2002"},{"key":"10.1016\/j.ejca.2003.11.028_BIB12","first-page":"4947","article-title":"Characterization of four new cell lines derived from human squamous carcinomas of the uterine cervix","volume":"47","author":"Kelland","year":"1987","journal-title":"Cancer Research"},{"key":"10.1016\/j.ejca.2003.11.028_BIB13","series-title":"Human Tumour Xenografts in Anticancer Drug Development","first-page":"57","article-title":"Establishment and response to chemotherapy of human cervical carcinoma xenografts","author":"Kelland","year":"1988"},{"key":"10.1016\/j.ejca.2003.11.028_BIB14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0167-8140(89)90070-4","article-title":"A comparison of the in vivo and in vitro radiation response of three human cervix carcinomas","volume":"16","author":"Kelland","year":"1989","journal-title":"Radiotherapy & Oncology"},{"key":"10.1016\/j.ejca.2003.11.028_BIB15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/oxfordjournals.annonc.a057678","article-title":"The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer agents","volume":"1","author":"Harrap","year":"1990","journal-title":"Annals Oncology"},{"key":"10.1016\/j.ejca.2003.11.028_BIB16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00686484","article-title":"Human ovarian carcinoma cell lines and companion xenografts","volume":"30","author":"Kelland","year":"1992","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejca.2003.11.028_BIB17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/1040-8428(93)90042-3","article-title":"New platinum antitumor complexes","volume":"15","author":"Kelland","year":"1993","journal-title":"Critical Reviews Oncology\/Hematology"},{"key":"10.1016\/j.ejca.2003.11.028_BIB18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/bjc.1993.5","article-title":"Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts","volume":"67","author":"Jones","year":"1993","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.ejca.2003.11.028_BIB19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0162-0134(99)00141-5","article-title":"Mini-review","volume":"77","author":"Kelland","year":"1999","journal-title":"Journal Inorganic Biochemistry"},{"key":"10.1016\/j.ejca.2003.11.028_BIB20","article-title":"ZD0473 phase II monotherapy trial in second-line ovarian cancer","volume":"20","author":"Gore","year":"2001","journal-title":"Proceedings of ASCO"},{"key":"10.1016\/j.ejca.2003.11.028_BIB21","first-page":"2063","article-title":"Cis-amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex","volume":"3","author":"Raynaud","year":"1997","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.ejca.2003.11.028_BIB22","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1054\/bjoc.2001.1796","article-title":"Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials","volume":"84","author":"Johnson","year":"2001","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.ejca.2003.11.028_BIB23","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/jnci\/86.24.1846","article-title":"Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model","volume":"86","author":"Casciari","year":"1994","journal-title":"Journal National Cancer Institute"},{"key":"10.1016\/j.ejca.2003.11.028_BIB24","first-page":"5263","article-title":"Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells","volume":"58","author":"Phillips","year":"1998","journal-title":"Cancer Research"},{"key":"10.1016\/j.ejca.2003.11.028_BIB25","series-title":"Tumor Models in Cancer Research","first-page":"293","article-title":"Models for evaluation of targeted therapies of metastatic disease","author":"Eccles","year":"2002"},{"key":"10.1016\/j.ejca.2003.11.028_BIB26","series-title":"Tumor Models in Cancer Research","first-page":"41","article-title":"Transplantable syngeneic rodent tumors","author":"Corbett","year":"2002"},{"key":"10.1016\/j.ejca.2003.11.028_BIB27","first-page":"1","article-title":"United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition)","volume":"77","author":"Workman","year":"1999","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.ejca.2003.11.028_BIB28","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1023\/A:1008333901925","article-title":"Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA","volume":"10","author":"Sausville","year":"1999","journal-title":"Annals. Oncology"},{"key":"10.1016\/j.ejca.2003.11.028_BIB29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00001813-200008000-00001","article-title":"Telomerase inhibitors","volume":"11","author":"Kelland","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2003.11.028_BIB30","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1124\/mol.61.5.1154","article-title":"A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity","volume":"61","author":"Gowan","year":"2002","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.ejca.2003.11.028_BIB31","first-page":"A3029","article-title":"Single agent activity and potentiation of the antitumour activity of paclitaxel and gemcitabine with the vascular targeting agent 5,6-dimethylxanthenone acetic acid (DMXAA) in human tumour xenografts","volume":"44","author":"Kelland","year":"2003","journal-title":"Proceedings of AACR"},{"key":"10.1016\/j.ejca.2003.11.028_BIB32","first-page":"3544","article-title":"Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer","volume":"7","author":"Kelland","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.ejca.2003.11.028_BIB33","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/jnci\/91.22.1940","article-title":"DT-diaphorase expression and tumor cell sensitivity to 17-allylamino,17-demethoxygeldanamycin, an inhibitor of heat shock protein 90","volume":"91","author":"Kelland","year":"1999","journal-title":"Journal National Cancer Institute"},{"key":"10.1016\/j.ejca.2003.11.028_BIB34","article-title":"Validation of pharmacodynamic endpoints for the HSP90 molecular chaperone inhibitor 17-allylamino 17-demethoxygeldanamycin (17AAG) in a human tumor xenograft model","volume":"42","author":"Banerji","year":"2001","journal-title":"Proceedings of AACR"},{"key":"10.1016\/j.ejca.2003.11.028_BIB35","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1038\/sj.onc.1203753","article-title":"Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone","volume":"19","author":"Clarke","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2003.11.028_BIB36","first-page":"164","article-title":"Source of oncofoetal ED-B containing fibronectin","volume":"60","author":"Midulla","year":"2000","journal-title":"Cancer Research"},{"key":"10.1016\/j.ejca.2003.11.028_BIB37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1006752903175","article-title":"Persistence of human vascular endothelium in experimental human prostate cancer bone tumors","volume":"18","author":"Nemeth","year":"2000","journal-title":"Clinical & Experimental Metastasis"},{"key":"10.1016\/j.ejca.2003.11.028_BIB38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nature Medicine"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804904000103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804904000103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T05:54:17Z","timestamp":1550210057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804904000103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0959804904000103"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2003.11.028","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}